Introduction
============

Colorectal cancer (CRC) is the most predominant malignant digestive tumor and fourth leading cause of cancer-associated mortality globally ([@b1-ol-0-0-8290]). The rate of recurrence and metastasis varies among patients with CRC, even between those at the same stages ([@b2-ol-0-0-8290],[@b3-ol-0-0-8290]). The lack of an ideal biological marker for the prognosis of patients with advanced colorectal cancer makes individualized treatment difficult ([@b4-ol-0-0-8290]). Therefore, the identification of novel markers and therapeutic targets for CRC is urgently required.

Transcription factor AP4 (TFAP4; also termed AP4 or AP-4) is a ubiquitously-expressed transcription factor belonging to the basic helix-loop-helix (bHLH)/leucine zipper subgroup of bHLH proteins, which exclusively form homodimers that bind to the CAGCTG E-box motif ([@b5-ol-0-0-8290]--[@b7-ol-0-0-8290]). It has been suggested that TFAP4 is involved in multiple essential cell processes, including cell proliferation, mitotic division, cell cycle progression and apoptosis ([@b8-ol-0-0-8290]--[@b10-ol-0-0-8290]). TFAP4 target genes also include stem cell markers including LGR5, and regulators of epithelial-mesenchymal transition including Snail Family Transcriptional Repressor 1 and Epithelial cadherin (E-cadherin) ([@b11-ol-0-0-8290],[@b12-ol-0-0-8290]). In addition, TFAP4 is encoded by a c-MYC target gene and is concomitantly upregulated with c-MYC in CRC and breast cancer ([@b11-ol-0-0-8290]).

Previous studies have demonstrated that TFAP4 is overexpressed in breast cancer, CRC and hepatocellular carcinoma, and that it is implicated in tumor prognosis ([@b13-ol-0-0-8290]--[@b15-ol-0-0-8290]). However, few studies have analyzed the clinical and functional roles of TFAP4 in CRC. The present study investigated TFAP4 expression in CRC and evaluated its prognostic significance in 187 CRC samples. Changes in CRC cell phenotype were studied by knockdown and overexpression of TFAP4. The results indicated that TFAP4 is involved in CRC progression, and as a result, targeted inhibition of TFAP4 may represent a novel approach for the treatment of CRC.

Materials and methods
=====================

### Patients

The present study included 187 patients with CRC who underwent surgery between January 2007 and January 2008 in the Department of Gastrointestinal Surgery at the First Affiliated Hospital of Sun Yat-sen University (Guangzhou, China). Patients were included in the present study if they had undergone a curative operation and had histologically proven colorectal cancer, and if they had not received preoperative chemotherapy and/or radiotherapy. Patients who succumbed to the disease within 3 months of surgical resection were not included. Information on clinicopathological characteristics, including age, sex, tumor size, differentiation, lymph node metastasis and liver metastasis, were retrieved from an inpatient database and are presented in [Table I](#tI-ol-0-0-8290){ref-type="table"}. Clinical and pathological classification and staging were determined according to the American Joint Committee on Cancer tumor-node-metastasis (TNM) staging system ([@b16-ol-0-0-8290]). Oncological outcome data were collected by telephone and the outpatient database every 3 months for the first year, every 6 months for the second to fifth year and every 12 months after 5 years. Only mortalities resulting specifically from CRC were defined as clinical endpoints.

All 187 patient specimens selected for immunohistochemical analysis were fixed in 10% formalin at room temperature for 24--48 h and embedded in paraffin. In addition, 30 pairs of fresh tumor tissues with matched adjacent normal tissues were stored in liquid nitrogen (at-196°C) until further use. Written informed consent was obtained from all patients for the use of their tissue samples. The Ethics Committee of the First Affiliated Hospital of Sun Yat-sen University approved the protocol of the present study.

### Immunohistochemistry (IHC)

Immunohistochemical staining was used to determine the expression levels of TFAP4 in CRC samples. Briefly, serial 4-mm sections were cut from paraffin-embedded blocks. For antigen retrieval, following deparaffinization and rehydration for 30 min at 50°C using a descending alcohol series (100 for 5 min, 100 for 5 min, 95 for 5 min, 80 for 5 min, 70% for 5 min, then two rinses with distilled water for 5 min each), sections were heated in 10 mmol/l citrate buffer (pH 6.0) at 125°C for 5 min and then cooled at room temperature. To block endogenous peroxidase, sections were treated in 0.3% hydrogen peroxide solution for 15 min at room temperature. Following incubation with goat serum (Maxim Biotech, Inc., Rockville, MD, USA) for 30 min at 37°C, polyclonal rabbit TFAP4 antibodies (dilution, 1:100; cat no. SAB1404461; Aviva Systems Biology Corporation, San Diego, CA, USA) were added and incubated overnight at 4°C in a moist chamber. Phosphate buffer saline (PBS) was used as a negative control. The following day, sections were stained with a goat anti-rabbit IgG horseradish peroxidase-conjugated secondary antibody for 30 min (dilution, 1:50; cat no. 4412S; Cell Signaling Technology, Inc., Danvers, MA, USA) at room temperature and visualized using 3,3′-diaminobenzidine hydrochloride for 10--15 sec at room temperature. Finally, the sections were counterstained with Mayer\'s hematoxylin for 1 min at room temperature, dehydrated, and images were captured.

To evaluate TFAP4 expression levels, two independent pathologists assessed the images using a semi-quantitative scoring method. In detail, the intensity of immunoreactivity was scored as: 0, negative staining; 1, weak staining; 2, moderate staining and 3, strong staining. The extent of immunoreactivity was scored according to the percentage of positive staining tumor cells in each microscopic view (5 fields of view for every slice), as follows: 0, 0--25% staining of tumor cells; 1, 26--50% staining of tumor cells; 2, 51--75% staining of tumor cells; and 3, 76--100% staining of tumor cells. The total IHC score was achieved by multiplying the scores of extent and intensity. High TFAP4 expression was defined as a total score ≥4, and a score \<4 was defined as low TFAP4 expression.

### Cell culture

The human colorectal cancer DLD-1, CaCo-2, HT-29, HCT-116, LS174T, LoVo and SW480 cell lines were obtained from the Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Shanghai, China). The immortalized colorectal epithelial NCM460 cell line was obtained from Sun Yat-sen University. All cells were cultured in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.) and incubated in a humidified incubator with 5% CO~2~ at 37°C.

### Cell transfection with plasmids and small interfering RNAs (siRNAs)

A total of three different TFAP4-specific siRNA sequences and a negative control siRNA (a scramble control produced by Guangzhou RiboBio Co., Ltd., Guangzhou, China) were used to knockdown the expression of TFAP4 in CRC cell lines. The sequences of the three siRNAs were as follows: si-001, 5′-GACGCATGCAGAGCATCAA-3′; si-002, 5′-GGACAAGGACGAAGGCATA-3′; and si-003, 5′-CCTCGGTCATCAACTCTGT-3′. The expression plasmids for TFAP-4 (EX-P0109-Lv201) and the control vector (EX-NEG-Lv201) were obtained from GeneCopoeia, Inc. (Rockville, MD, USA). When cells reached \~50% confluency, 50 µM siRNA per well was transfected, performed using Lipofectamine 3000 reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) following the manufacturer\'s protocol. Transfection efficiency was confirmed by detecting the expression change of TFAP4 using western blotting and quantitative polymerase chain reaction (qPCR) as described below. Following transfection for 48 h, the cells were harvested and moved into the 96-well culture plates, 6-well plates and transwell chambers, for use in the proliferation, migration and invasion assays, respectively.

### Cell proliferation assay

Cell proliferation was examined using Cell Counting Kit-8 (Dojindo Molecular Technologies, Inc., Kumamoto, Japan) according to the manufacturer\'s protocol. Briefly, transfected and control cells (cells transfected with the control vector and cells transfected with the control siRNA) were seeded onto 96-well culture plates (3×10^3^ cells/well) and cultured for 4 days. At each 24-h interval, 10 µl CCK-8 solution was added to each well and incubated for 2 h at 37°C. Using a microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA), the absorbance was measured at 450 nm.

### Wound healing assay

Cells were seeded onto a 6-well plate and grown to 90% confluence. Confluent cells were then scratched using a 200-ml pipette tip. Following rinsing three times with PBS to remove detached cells, the remaining cells were incubated in serum-deprived medium (RPMI-1640 medium with 1% FBS; Gibco; Thermo Fisher Scientific, Inc.) at 37°C for 48 h. The wound status was recorded using an inverted microscope at a magnification of ×40 (Olympus Corporation, Tokyo, Japan) at 0, 24 and 48 h after scratching. Distances covered by migrated cells were quantified via ImageJ software (version 1.48; National Institutes of Health, Bethesda, MD, USA). The experiment was performed three times.

### Migration and invasion assay

Cell invasion and migratory potential were evaluated in 24-well plates using Transwell chambers (8 µm pore membrane; BD Biosciences, Franklin Lakes, NJ, USA). For the migration assay, cells (5×10^4^) were seeded into the upper chamber. For the invasion assay, 1×10^5^ cells were seeded into the upper chamber, where the membrane was covered with matrix gel (BD Biosciences). To create a chemoattractant, cells were suspended in 100 µl serum-free RPMI-1640 medium in the upper chamber, whereas the lower chamber contained 500 µl RPMI-1640 with 10% FBS. After 20 h of incubation at 37°C for the migration assay and 24 h for the invasion assay, the membranes were fixed with 4% paraformaldehyde for 20 min at room temperature and stained with 0.1% crystal violet at room temperature for 20 min. The cells on the upper surface were removed using a cotton swab. The number of invaded and migrated cells was quantified by counting five different fields of view under a light microscope at a magnification of ×200.

### Western blot analysis

Human CRC tissues and cells were lysed in ice-cold radioimmunoprecipitation assay lysis buffer (Beyotime Institute of Biotechnology, Haimen, China) with added protease and phosphatase inhibitors (Beyotime Institute of Biotechnology). Following removal of the cell debris by centrifugation (13,000 × g at 4°C for 20 min), the protein concentration was measured using the Bicinchoninic Acid Protein Assay kit (Beyotime Institute of Biotechnology). Equal amounts of protein (20 µg) were separated on 10% SDS-PAGE gels and transferred to polyvinylidene fluoride membranes (EMD Millipore, Billerica, MA, USA). Following blocking with 5% bovine serum albumin (Beyotime Institute of Biotechnology) for 1 h at room temperature, the membranes were incubated overnight at 4°C with the following antibodies: TFAP4 (dilution, 1:1,000; cat no. SAB1404461; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) and β-tubulin (dilution, 1:10,000; cat no. 86298; Cell Signaling Technology, Inc.). Following washing with TBS containing Tween-20, the membranes were incubated with secondary antibodies \[dilution, 1:5,000; goat anti-rabbit horseradish peroxidase (HRP)-conjugated secondary antibody, cat no. 7074 and goat anti-mouse HRP-conjugated secondary antibody, cat no. 7076; Cell Signaling Technology\] at room temperature for 1 h. Finally, proteins on the membranes were visualized using enhanced chemiluminescence reagents (EMD Millipore) in the ImageQuant Las4000mini detection system (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA).

### RNA extraction and reverse transcription-qPCR (RT-qPCR)

Total RNA was isolated from the cells or tissues using TRIzol reagent (Takara Bio, Inc., Otsu, Japan) according to the manufacturer\'s protocol, and 500 ng RNA was reverse-transcribed into cDNA using the Prime Script RT Master Mix (Takara Bio, Inc.) according to the manufacturer\'s protocol. RT-qPCR was performed with the resultant cDNA as a template using the SYBR Premix Ex *Taq* kit (RNaseH Plus; Takara Bio, Inc.) according to the manufacturer\'s protocol in the Bio-Rad CFX96 cycler (Bio-Rad Laboratories, Inc.) under the following conditions: 95°C for 30 sec, 40 cycles of 95°C for 3 sec, 60°C for 30 sec and 72°C for 50 sec. PCR reactions were performed in triplicate and repeated three times. The relative level of TFAP4 mRNA was calculated using the 2^−ΔΔCq^ method ([@b17-ol-0-0-8290]) with normalization to GAPDH. Primers were designed as follows: TFAP4 forward, 5′-GAGCCAGCCTGGGATTGTC-3′; TFAP4 reverse, 5′-GTGCTTAAAGGAGAAAGAAGAAAACC-3′; GAPDH forward, 5′-TGTTGCCATCAATGACCCCTT-3′; and GAPDH reverse, 5′-CTCCACGACGTACTCAGCG-3′.

### Statistical analysis

All data were analyzed using SPSS 19.0 statistical software (IBM SPSS, Armonk, NY, USA). The data were presented as the mean ± the standard deviation. The association between TFAP4 expression and clinicopathological parameters was analyzed using the χ^2^ test. Survival analysis was performed using the Kaplan-Meier method and the log-rank test. The significant prognostic factors in the univariate survival analysis were subsequently investigated with Cox\'s proportional hazards model for multivariate survival analysis. Other comparisons between two groups were made using Student\'s t-tests, with one-way analysis of variance (followed by Tukey\'s post hoc test) used for comparisons between more than two groups. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### TFAP4 expression and prognosis in CRC

To investigate the function of TFAP4 in CRC, TFAP4 expression was examined in human CRC tissue and cell lines. RT-qPCR experiments revealed that TFAP4 mRNA expression was increased in all seven CRC cell lines compared with the immortalized colorectal epithelial NCM460 cell line ([Fig. 1A](#f1-ol-0-0-8290){ref-type="fig"}). Western blotting revealed similar results in terms of protein TFAP4 expression ([Fig. 1B](#f1-ol-0-0-8290){ref-type="fig"}). In CRC tissues, the TFAP4 mRNA expression level was 4.3-fold higher than that of adjacent normal tissues ([Fig. 1C](#f1-ol-0-0-8290){ref-type="fig"}). Western blotting results also revealed that with the exception of in lane number 3, TFAP4 protein expression levels were markedly increased in the tumor tissues compared with matched adjacent normal tissues ([Fig. 1D](#f1-ol-0-0-8290){ref-type="fig"}).

Next, TFAP4 protein expression was examined in 187 CRC tissues by IHC. Representative images of cytoplasmic and nuclear TFAP4 protein expression in the tumor cells are presented in [Fig. 2A](#f2-ol-0-0-8290){ref-type="fig"}. The positive expression rate was 76.5% (143 of 187). To evaluate the association between TFAP4 expression and clinicopathological parameters, patients were divided into two groups based on the aforementioned IHC score assessment system. The results revealed that high TFAP4 expression was positively associated with TNM stage (P\<0.001), lymph node invasion (P\<0.001), liver metastasis (P\<0.001) and differentiation (P=0.024). More details are presented in [Table I](#tI-ol-0-0-8290){ref-type="table"}.

Since TFAP4 overexpression was associated with CRC progression, the present study investigated whether high TFAP4 expression was a prognostic factor in patients with CRC. Kaplan-Meier survival analysis demonstrated that high TFAP4 expression was significantly associated with poor overall survival (OS), and was also a significant prognostic factor within stage I--II and stage III--IV patients (P\<0.001; [Fig. 2B-D](#f2-ol-0-0-8290){ref-type="fig"}). In addition, univariate and multivariate Cox regression analysis was performed to examine whether TFAP4 expression was an independent prognostic factor. Univariate analysis revealed that high TFAP4 expression, degree of differentiation, lymph node metastasis, liver metastasis and TNM stage were prognostic factors for OS time. However, in the multivariate Cox regression analysis, only liver metastasis and high TFAP4 expression were associated with poor OS ([Table II](#tII-ol-0-0-8290){ref-type="table"}). The present data demonstrated that high TFAP4 expression was an independent prognostic factor for patients with CRC (hazard ratio=2.607; 95% confidence interval, 1.469--4.627; P\<0.001).

### TFAP4 promotes colorectal cancer cell proliferation, migration and invasion in vitro

To determine the function of TFAP4 in CRC cells, cell proliferation, motility and invasion assays were performed to evaluate the effect of TFAP4 overexpression or knockdown on CRC cell lines *in vitro*. The SW480 cell line, which exhibits relatively low TFAP4 expression, was transfected with a TFAP4-expressing plasmid (V-TFAP4). To knockdown TFAP4, the HT29 cell line, which expresses a relatively high level of TFAP4, was transfected with specific siRNAs. RT-PCR and western blot analysis demonstrated that TFAP4 expression was reduced by siRNA and increased by cDNA transfection, respectively ([Fig. 3](#f3-ol-0-0-8290){ref-type="fig"}). The results indicated that si-002 was the most effective sequence in terms of TFAP4 inhibition. Therefore, si-002 was used for subsequent experiments, and the negative control siRNA (50 nM) was used as a control.

In cell proliferation assays, overexpression of TFAP4 was revealed to significantly promote proliferation, while downregulation of TFAP4 inhibited CRC cell proliferation (P\<0.05; [Fig. 4](#f4-ol-0-0-8290){ref-type="fig"}). Compared with control cells, overexpression of TFAP4 stimulated increased migration and invasion, whereas knockdown had an inhibitory effect on these phenomena (P\<0.05; [Figs. 5](#f5-ol-0-0-8290){ref-type="fig"}--[7](#f7-ol-0-0-8290){ref-type="fig"}). In detail, in the wound healing assays, knockdown of TFAP4 repressed the cell motility of CRC cells, but overexpression of TFAP4 improved their motility ([Fig. 5](#f5-ol-0-0-8290){ref-type="fig"}). Transwell migration assays revealed that ectopic expression of TFAP4 stimulated tumor cell migration, and that the number of migrated cells was reduced following TFAP4 knockdown ([Fig. 6](#f6-ol-0-0-8290){ref-type="fig"}). Similarly, the invasive ability was improved in TFAP4-overexpressed CRC cells; however, TFAP4 knockdown in CRC cells indicated the opposite effect ([Fig. 7](#f7-ol-0-0-8290){ref-type="fig"}). Taken together, the present data demonstrated that TFAP4 promoted CRC proliferation, migration and invasion *in vitro*.

Discussion
==========

In the present study, high expression of TFAP4 in CRC cell lines and specimens compared with normal cells and tissue was observed. Multivariate survival analysis revealed that the TFAP4 expression level in CRC was an independent prognostic factor. Functional analysis demonstrated that TFAP4 contributed to CRC cell proliferation, migration and invasion.

TFAP4 was initially identified as a cellular protein that binds to the simian virus 40 enhancer and activates viral late gene transcription ([@b18-ol-0-0-8290]). TFAP4 controls transcriptional networks during cellular differentiation through homodimer formation and binding to the symmetrical DNA sequence, CAGCTG ([@b5-ol-0-0-8290]). High TFAP4 expression has been reported in CRC, breast cancer and hepatocellular carcinoma ([@b13-ol-0-0-8290]--[@b15-ol-0-0-8290]). These results also indicate that TFAP4 overexpression is associated with a worse prognosis.

Previous studies have established a functional role for TFAP4 in several crucial aspects of tumor progression, including proliferation, apoptosis ([@b9-ol-0-0-8290],[@b11-ol-0-0-8290],[@b12-ol-0-0-8290],[@b19-ol-0-0-8290]), transformation ([@b10-ol-0-0-8290]), invasion, metastasis ([@b12-ol-0-0-8290]) and chemoresistance ([@b13-ol-0-0-8290],[@b20-ol-0-0-8290]), indicating that TFAP4 is potentially involved in tumorigenesis. Loss of p21 expression is associated with the promotion of neoplasia, tumorigenesis and progression in CRC ([@b21-ol-0-0-8290]). The p21 gene encodes a cell cycle-dependent kinase inhibitor, which is induced by p53 and numerous other anti-proliferative factors ([@b22-ol-0-0-8290]). Jackstadt *et al* ([@b9-ol-0-0-8290],[@b10-ol-0-0-8290]) reported that TFAP4 promotes cell proliferation via direct repression of p21 by occupying four CAGCTG motifs in the basic region of the p21 promoter. Since TFAP4 is a c-MYC target gene and is upregulated in colorectal tumors, and this upregulation is a hallmark of CRC ([@b23-ol-0-0-8290]), it was hypothesized that TFAP4 may be involved in tumor progression. In the present study, knockdown of endogenous TFAP4 inhibited CRC cell proliferation, whereas ectopic expression of TFAP4 enhanced these capacities. These results are consistent with previous studies ([@b12-ol-0-0-8290],[@b14-ol-0-0-8290]) highlighting the involvement of TFAP4 in the progression of CRC.

In gastrointestinal adenocarcinoma, TFAP4 promotes cell proliferation by affecting key regulators of the cell cycle ([@b9-ol-0-0-8290],[@b20-ol-0-0-8290]). In breast cancer, TFAP4 suppresses cell proliferation by inducing the c-Jun N-terminal kinase/TFAP4/protein tyrosine phosphatase, non-receptor type 6 signaling pathway ([@b13-ol-0-0-8290]). The contradictory effect of TFAP4 in colorectal cancer and breast cancer suggests that TFAP4 performs a differential role in cell proliferation and that TFAP4-activated signaling pathways may be tumor-specific. The present study demonstrated that TFAP4 promotes the proliferation of CRC cells. The results were consistent with those of previous studies, demonstrating that TFAP4 serves an essential function in tumor cell proliferation ([@b9-ol-0-0-8290],[@b20-ol-0-0-8290]).

Jackstadt *et al* ([@b12-ol-0-0-8290]) reported that TFAP4 is a novel regulator of the epithelial-mesenchymal transition (EMT), which contributes to the metastatic processes in colorectal cancer. TFAP4 directly represses E-cadherin via a non-canonical TFAP4-binding motif and induces neural-cadherin, the process of which is a hallmark of the EMT ([@b12-ol-0-0-8290]). Consistent with the study by Jackstadt *et al* ([@b12-ol-0-0-8290]), the present study revealed that TFAP4 expression is also positively associated with liver metastasis, and that TFAP4 overexpression promotes cell migration and invasion *in vitro*. These results indicated that TFAP4 activation may also induce EMT and enhance the migration and invasion of CRC cells. However, additional studies on the molecular mechanisms underlying these events are required.

In summary, consistent with the function of TFAP4 in numerous different aspects of tumor malignancy, the present study demonstrated that TFAP4 is overexpressed in colorectal cancer and that TFAP4 is associated with poor clinical outcome in patients with CRC. In addition, TFAP4 is an independent prognostic factor for the OS of patients with CRC. Overexpression of TFAP4 promotes cell proliferation, migration and invasion. Future studies should focus on the identification of TFAP4-interacting proteins and the validation of the potential effectiveness of TFAP4 as a target for intervening with CRC progression.
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![TFAP4 overexpression in CRC cells and tissues, as assessed using reverse transcription-quantitative polymerase chain reaction analysis and western blotting. (A) TFAP4 mRNA expression in CRC cell lines was higher than in a normal colonic epithelial cell line. (B) Expression of TFAP4 was increased in cancer tissues. The TFAP4 (C) mRNA and (D) protein expression levels of colorectal cancer tissues were higher than that of matched adjacent non-cancerous tissues (\*P\<0.001). Representative gel images are presented. TFAP4, transcription factor AP4.](ol-15-05-7545-g00){#f1-ol-0-0-8290}

![Prognostic significance of TFAP4 expression in patients with colorectal cancer. (A) Representative images of TFAP4 expression in normal tissue, high differentiation, moderate differentiation and low differentiation. Kaplan-Meier analysis of overall survival based on TFAP4 expression in (B) all patients, (C) stage I--II patients and (D) stage III--IV patients (\*P\<0.001). TFAP4, transcription factor AP4.](ol-15-05-7545-g01){#f2-ol-0-0-8290}

![Transfection efficiency was confirmed by RT-qPCR and western blot analysis. The (A) mRNA and (B) protein levels of TFAP4 were increased following overexpression of TFAP4 in SW480 cells. (C) RT-qPCR and (D) western blot analysis revealed that si-002 was the most efficient siRNA for TFAP4 inhibition. RT-qPCR, reverse transcription-quantitative polymerase chain reaction; si, small interfering; TFAP4, transcription factor AP4.](ol-15-05-7545-g02){#f3-ol-0-0-8290}

![TFAP4 promotes cell proliferation in colorectal cancer cell lines. TFAP4 protein level was increased following overexpression of TFAP4 in SW480 cells and decreased following knockdown of TFAP4 in HT-29 cells. Cell Counting Kit-8 assays revealed that overexpressed TFAP4 stimulated tumor cell growth, whereas knockdown of TFAP4 inhibited cell growth ability. \*P\<0.05 vs. 0 h. TFAP4, transcription factor AP4; si, small interfering; OD, optical density.](ol-15-05-7545-g03){#f4-ol-0-0-8290}

![TFAP4 promotes cell motility in colorectal cancer cell lines. Compared with control cells, knockdown of TFAP4 repressed the cell motility of HT-29 cells. Overexpression of TFAP4 stimulated cell motility in SW480 cells compared with that of control cells. Images presented at magnification, ×40. \*P\<0.05, with comparisons indicated by lines. TFAP4, transcription factor AP4; si, small interfering.](ol-15-05-7545-g04){#f5-ol-0-0-8290}

![TFAP4 promotes cell migration in colorectal cancer cell lines. Transwell migration assays revealed that ectopic expression of TFAP4 stimulated tumor cell migration, whereas knockdown of TFAP4 had the opposite effect. Images presented at magnification, ×100. \*P\<0.05, with comparisons indicated by lines. TFAP4, transcription factor AP4; si, small interfering.](ol-15-05-7545-g05){#f6-ol-0-0-8290}

![TFAP4 promotes cell invasion in colorectal cancer cell lines. Overexpression of TFAP4 induced the invasion of more tumor cells through the membrane. The number of invaded cells was reduced following TFAP4 knockdown. Images presented at magnification, ×100. \*P\<0.05, with comparisons indicated by lines. TFAP4, transcription factor AP4; si, small interfering.](ol-15-05-7545-g06){#f7-ol-0-0-8290}

###### 

Association between TFAP4 expression and the clinicopathological characteristics of patients with colorectal cancer.

                                        TFAP4 expression, n (%)               
  ------------------------------- ----- ------------------------- ----------- ---------
  Sex                                                                         0.544
    Male                          109   58 (56.3)                 51 (60.7)   
    Female                        78    45 (43.7)                 33 (39.3)   
  Age, years                                                                  0.383
    \<60                          80    47 (45.6)                 33 (39.3)   
    ≥60                           107   56 (54.7)                 51 (60.7)   
  Location of primary tumor                                                   0.047
    Colon                         104   64 (62.1)                 40 (47.6)   
    Rectal                        83    39 (37.8)                 44 (52.4)   
  Tumor size, cm                                                              0.632
    \<5                           106   60 (58.3)                 46 (54.8)   
    ≥5                            81    43 (41.7)                 38 (45.2)   
  T classification                                                            0.276
    T1 + T2                       33    21 (20.4)                 12 (14.3)   
    T3 + T4                       154   82 (79.6)                 72 (85.7)   
  Lymph node invasion                                                         \<0.001
    No                            116   77 (74.8)                 39 (46.4)   
    Yes                           71    26 (25.2)                 45 (53.6)   
  Metastasis                                                                  \<0.001
    M0                            163   97 (94.2)                 64 (76.2)   
    M1                            26    6 (5.8)                   20 (23.8)   
  TNM stage                                                                   \<0.001
    I--II                         107   74 (71.8)                 33 (39.3)   
    III--IV                       80    29 (28.2)                 51 (60.7)   
  Pathological differentiation                                                0.024
    Well                          14    12 (11.7)                 2 (2.4)     
    Moderate                      138   76 (73.8)                 62 (73.8)   
    Poor                          35    15 (14.6)                 20 (23.8)   
  Therapeutic strategy                                                        0.392
    Surgery only                  111   64 (62.1)                 47 (56.0)   
    Surgery + chemotherapy        76    39 (37.9)                 37 (44.0)   
  Vital status (as followed up)                                               \<0.001
    Alive                         124   83 (80.6)                 41 (48.8)   
    Dead                          63    20 (19.4)                 43 (51.2)   

Assessed using the χ^2^ test. TFAP4, transcription factor AP4; TNM, tumor-node-metastasis.

###### 

Univariate and multivariate analyses of various potential prognostic factors in patients with colorectal cancer.

                               Univariate analysis     Multivariate analysis                          
  ---------------------- ----- ----------------------- ----------------------- ---------------------- ---------
  Age, years                   1.668 (0.981--2.836)    0.059                   1.552 (0.875--2.783)   0.140
    \<60                 80                                                                           
    ≥60                  107                                                                          
  Sex                          1.373 (0.818--2.304)    0.231                   1.486 (0.864--2.557)   0.152
    Male                 109                                                                          
    Female               78                                                                           
  Tumor size, cm               1.409 (0.860--2.311)    0.174                   1.105 (0.658--1.858)   0.705
    \<5                  106                                                                          
    ≥5                   81                                                                           
  Therapeutic strategy         0.942 (0.568--1.560)    0.816                   0.770 (0.433--1.370)   0.374
    Sur                  111                                                                          
    Sur + chemo          76                                                                           
  Differentiation              0.161 (0.022--1.161)    0.070                   0.334 (0.044--2.528)   0.288
    Well                 14                                                                           
    Moderate/poor        173                                                                          
  Depth of invasion            1.581 (0.753--3.320)    0.226                   1.121 (0.511--2.460)   0.775
    T1-T2                33                                                                           
    T3-T4                154                                                                          
  Lymph node invasion          2.343 (1.427--3.848)    0.001                   1.594 (0.526--4.828)   0.410
    Present              71                                                                           
    Absent               116                                                                          
  Metastasis                   5.957 (3.425--10.360)   \<0.001                 3.833 (1.868--7.863)   \<0.001
    Present              26                                                                           
    Absent               163                                                                          
  TNM stage                    2.880 (1.734--4.782)    \<0.001                 1.060 (0.315--3.569)   0.925
    I--II                107                                                                          
    III--IV              80                                                                           
  TFAP4 expression             3.703 (2.174--6.306)    \<0.001                 2.607 (1.469--4.627)   0.001
    High                 84                                                                           
    Low                  103                                                                          

HR, hazard ratio; CI, confidence interval; Sur, surgery only; Sur + chemo, surgery plus adjuvant chemotherapy; TNM, tumor-node-metastasis; TFAP4, transcription factor AP4.
